BioCryst to Present at Upcoming Investor Conferences
Rhea-AI Summary
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its participation in three major investor conferences in May 2025:
- Citizens Life Sciences Conference in New York - May 8, 2025, at 9:00 a.m. ET
- Bank of America 2025 Health Care Conference in Las Vegas - May 14, 2025, at 1:40 p.m. ET
- RBC Capital Markets Global Healthcare Conference in New York - May 21, 2025, at 3:05 p.m. ET
Investors and interested parties can access live audio webcasts and replay recordings of these presentations through the Investors & Media section on BioCryst's website at biocryst.com.
Positive
- Increased visibility through participation in three major healthcare investor conferences
- Multiple opportunities for investor engagement across different financial institutions (Citizens, Bank of America, RBC Capital Markets)
Negative
- None.
News Market Reaction – BCRX
In the trading session that priced this news, BCRX gained 4.86%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
- Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 9:00 a.m. ET.
- Bank of America 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 1:40 p.m. ET.
- 2025 RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 21, 2025, at 3:05 p.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
